USPTO Examiner FRUMKIN JESSE P - Art Unit 1685

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19178769CONDITIONAL MULTICAPITATE NEURAL NETWORKS FOR AI-BASED PROTEIN AND DRUG DESIGNApril 2025August 2025Allow430YesNo
18874453SYSTEMS AND METHODS FOR IDENTIFYING PEPTIDES BY SAMPLING AND FILTERINGDecember 2024January 2026Allow1320YesNo
18740810UNIFORM RESOURCE IDENTIFIER ENCODINGJune 2024December 2025Allow1830YesNo
18434510HLA Tissue Matching And Methods ThereforFebruary 2024February 2026Allow2400YesNo
18540814Method for the Compression of Genome Sequence DataDecember 2023October 2025Allow2220YesNo
18230296CHEMICAL METHODS FOR NUCLEIC ACID-BASED DATA STORAGEAugust 2023February 2026Abandon3040YesNo
18340792METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID SEQUENCESJune 2023March 2026Abandon3310NoNo
18128557TECHNIQUES FOR MODELLING AND OPTIMIZING DIALYSIS TOXIN DISPLACER COMPOUNDSMarch 2023December 2025Allow3310YesNo
17963665IDENTIFICATION OF CLONAL NEOANTIGENS AND USES THEREOFOctober 2022October 2025Allow3630YesNo
17946901DYNAMIC DATA SET MODIFICATION AND MAPPINGSeptember 2022June 2025Allow3300YesNo
17888439GENOTYPING POLYPLOID LOCIAugust 2022August 2025Abandon3620NoNo
17804416COMPARATIVELY-REFINED POLYGENIC RISK SCORE GENERATION MACHINE LEARNING FRAMEWORKSMay 2022February 2026Allow4500NoNo
17763401METHOD AND SYSTEM FOR PERFORMING NON-INVASIVE GENETIC TESTING USING AN ARTIFICIAL INTELLIGENCE (AI) MODELMarch 2022November 2025Allow4300YesNo
17654520MODELING THE CHEMICAL COMPOSITION OF A BIOLOGICAL CELL WALLMarch 2022March 2025Abandon3610NoNo
17456519Network Medicine Framework for Identifying Drug Repurposing OpportunitiesNovember 2021January 2026Allow5010NoNo
17534542Method for analyzing relationship between communication path and heat resistance of lipaseNovember 2021February 2026Abandon5010NoNo
17530484INTRADIALYTIC ANALYSIS METHOD AND ANALYSIS APPARATUS FOR DIALYSISNovember 2021January 2026Allow5020YesNo
17484179GENE SIGNATURES FOR CANCER PROGNOSISSeptember 2021November 2025Abandon4910NoNo
17482405Machine-Learned Quality Control for Epigenetic DataSeptember 2021October 2025Abandon4910NoNo
17361781ANTIMICROBIC SUSCEPTIBILITY TESTING USING MACHINE LEARNINGJune 2021August 2025Abandon5010NoNo
17361827METHODS OF PREDICTING AGE, AND IDENTIFYING AND TREATING CONDITIONS ASSOCIATED WITH AGING USING SPECTRAL CLUSTERING AND DISCRETE COSINE TRANSFORMJune 2021September 2025Abandon5110NoNo
17349851BIOLOGICAL KIN RECOGNITION METHOD AND SYSTEM BASED ON UNSUPERVISED CLUSTERING OF mRNA BASEJune 2021August 2025Abandon5010NoNo
17349830METHODS AND SYSTEMS FOR DETECTING GENETIC FUSIONS TO IDENTIFY A LUNG DISORDERJune 2021July 2025Abandon4910YesNo
17296654METHOD FOR DETECTING AND MONITORING THE FORMATION OF BIOFILMSMay 2021March 2025Abandon4600NoNo
17320324PREDICTING CHANGES IN MEDICAL CONDITIONS USING MACHINE LEARNING MODELSMay 2021February 2026Abandon5730NoNo
17291224PREDICTIVE METHODS IN BREAST CANCERMay 2021January 2026Abandon5620NoNo
17290924ENHANCED DETECTION OF TARGET DNA BY FRAGMENT SIZE ANALYSISMay 2021April 2025Allow4720YesNo
17243473VIRTUALLY MONITORING BLOOD PRESSURE LEVELS IN A PATIENT USING MACHINE LEARNING AND DIGITAL TWIN TECHNOLOGYApril 2021November 2025Allow5530YesNo
17195339CODES TO DETECT INSERTION AND DELETION ERRORS IN A DENSE STORAGE MEDIUMMarch 2021April 2025Allow4900YesNo
17172668METHOD AND APPARATUS FOR PREDICITING NEUROLOGICAL OUTCOME POST-CARDIAC ARRESTFebruary 2021July 2025Allow5320YesNo
16972458MULTI-DOMAIN PROTEINS WITH INCREASED NATIVE STATE COLLOIDAL STABILITYDecember 2020February 2025Allow5020NoNo
17058981LIPID NANOTABLETNovember 2020March 2025Allow5210NoNo
16890542DATABASE SNAPSHOT AND BACKUP MANAGEMENT WITH RECOVERABLE CHAINSJune 2020November 2024Allow5430YesNo
16545751Systems and Methods for Compressing Genetic Sequencing Data and Uses ThereofAugust 2019January 2025Allow6010YesNo
16534257Methods and Systems for Protein IdentificationAugust 2019February 2026Abandon60101YesNo
16341361METHOD AND SYSTEM FOR THE TRANSMISSION OF BIOINFORMATICS DATAApril 2019May 2025Allow6040YesNo
16019332METHODS AND APPARATUSES FOR PREDICTION OF MECHANISM OF ACTIVITY OF COMPOUNDSJune 2018May 2025Allow6051YesYes
15917419BIOPROCESS METHOD AND SYSTEM VIA AUTOMATED LABORATORY SYSTEMSMarch 2018September 2025Abandon6081YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FRUMKIN, JESSE P.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
1.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FRUMKIN, JESSE P - Prosecution Strategy Guide

Executive Summary

Examiner FRUMKIN, JESSE P works in Art Unit 1685 and has examined 24 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.

Allowance Patterns

Examiner FRUMKIN, JESSE P's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FRUMKIN, JESSE P receive 2.33 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FRUMKIN, JESSE P is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by FRUMKIN, JESSE P. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.5% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 28.6% are granted (fully or in part). This grant rate is in the 16% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.